@entity2779 . A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of XXXX .

@entity1 @entity712 @entity1165 @entity11797 @entity591 @entity73163 @entity6237 @entity3303 @entity5126 @entity7306 @entity1540 @entity1406 @entity67 @entity943 @entity2779
@entity2779 is a Class I antiarrhythmic agent with weak beta-adrenoceptor antagonist activity which can be given both intravenously and orally. Dosage must be individualised because of dose-dependent pharmacokinetics, a wide range of clinically effective plasma concentrations (64 to 3271 micrograms/L) after comparable doses, the presence of an active metabolite ( @entity73163 ) and genetically determined metabolic oxidation. In non-comparative studies @entity2779 450 and 900 mg/day orally significantly suppressed @entity1540 in 96% and 75% of @entity1 , respectively, and abolished @entity1165 in 75% of @entity1 . Efficacy was confirmed in placebo-controlled studies in which @entity2779 300 to 900mg daily suppressed @entity1540 (greater than 80%) in 77% of @entity1 ; 87% of @entity1 had significant reductions in couplets and abolition of @entity1165 . In @entity1 with @entity943 refractory to other antiarrhythmic agents, @entity2779 450 to 1200 mg/day suppressed @entity943 in 63% of @entity1 (in long term therapy 66%). Electrically induced @entity943 were prevented by intravenously administered @entity2779 in 12 to 23% of @entity1 . However, long term oral therapy was effective in 77% of @entity1 selected using programmed electrical stimulation. @entity2779 was also effective in suppressing atrial and AV nodal/junctional re-entrant @entity591 involving accessory pathways. A limited number of comparisons with other antiarrhythmic drugs indicate that the antiarrhythmic efficacy of @entity2779 is superior or similar to that of @entity5126 , @entity7306 and @entity11797 , and comparable to that of @entity3303 ( @entity3303 ), @entity6237 and @entity1406 against @entity943 and a smaller number of @entity943 . Cardiovascular side effects indicate a proarrhythmic effect similar to that with other Class I drugs, occasional precipitation of @entity712 and conduction abnormalities; the latter two occur more often in @entity1 with underlying @entity67 . Non-cardiovascular side effects (neurological, gastrointestinal) are well tolerated and generally resolve with continued therapy or dosage reduction. Thus, @entity2779 is an effective antiarrhythmic agent, and is a useful addition to currently available drugs, although further studies will be required to determine clearly its place in therapy compared with more established antiarrhythmic drugs.
